Oral GLP ‐ 1RA TERN ‐601 for Adults With Obesity/Overweight: Placebo‐Controlled, Multiple‐Ascending‐Dose, Phase 1 and 2 Studies
Obesity · 2026
DOI: 10.1002/oby.70271 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Obesity, 2026. Verfasst von W Timothy Garvey und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, Alabama, USA. Hauptthemen laut MEDLINE: Obesity, Overweight, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Terns Pharmaceuticals.
Abstract (Originalsprache)
Objective
The safety, tolerability, pharmacokinetics, and efficacy of TERN‐601, a once‐daily, oral small‐molecule glucagon‐like peptide‐1 (GLP‐1) receptor agonist, were studied in Phase 1 and 2 clinical studies.
Methods
The Phase 1 (28‐day) and Phase 2 (12‐week), randomized, double‐blind, placebo‐controlled, multiple‐ascending‐dose studies evaluated the safety, tolerability, pharmacokinetics, and efficacy (change in weight, appetite, and gastric emptying) of TERN‐601 for adults with obesity or overweight.
Results
In the Phase 1 study, TERN‐601 produced dose‐dependent weight loss over 28 days, with statistically significant reductions versus placebo at all doses. Treatment was associated with GLP‐1–consistent pharmacodynamic effects, including reduced appetite and delayed gastric emptying. In the Phase 2 study, TERN‐601 doses ≥ 500 mg resulted in significantly greater mean percentage weight loss at Week 12 versus placebo. Gastrointestinal treatment‐emergent adverse events were consistent with the GLP‐1 receptor agonist class and dose‐related. Three participants in the Phase 2 study experienced transaminase elevations consistent with potential drug‐induced liver injury.
Conclusions
TERN‐601 demonstrated modest, dose‐dependent weight loss with a gastrointestinal tolerability profile consistent with GLP‐1 receptor agonists. However, liver safety findings observed in the Phase 2 study led to clinical development discontinuation. These data contribute to the overall understanding of oral small‐molecule GLP‐1 receptor agonists in obesity. Trial Registration ClinicalTrials.gov identifier: NCT06854952
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, Alabama, USA.
- University of Texas Southwestern Medical Center, Dallas, Texas, USA.
- Monroe Biomedical Research, Louisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky, USA.
- Flourish Research, San Antonio, Texas, USA.
- Arizona Liver Health, Chandler, Arizona, USA.
- Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts, USA.
ORCID-Profile: W Timothy Garvey, Harold E Bays, Erin Castelloe, Cara Nelson
Förderung
- Terns Pharmaceuticals
Zitieren
APA
Garvey, W. T., Rosenstock, J., Bays, H. E., Denham, D., Kohli, A., Haines, M., Jones, C., Kwan, E., Castelloe, E., Marmon, T., Kuriakose, E., & Nelson, C. (2026). Oral GLP ‐ 1RA TERN ‐601 for Adults With Obesity/Overweight: Placebo‐Controlled, Multiple‐Ascending‐Dose, Phase 1 and 2 Studies. Obesity. https://doi.org/10.1002/oby.70271
Vancouver
Garvey WT, Rosenstock J, Bays HE, Denham D, Kohli A, Haines M, et al. Oral GLP ‐ 1RA TERN ‐601 for Adults With Obesity/Overweight: Placebo‐Controlled, Multiple‐Ascending‐Dose, Phase 1 and 2 Studies. Obesity. 2026. doi:10.1002/oby.70271
BibTeX
@article{Garvey2026,
author = {Garvey, W Timothy and Rosenstock, Julio and Bays, Harold E and Denham, Douglas and Kohli, Anita and Haines, Melanie and Jones, Christopher and Kwan, Ellen and Castelloe, Erin and Marmon, Tonya and Kuriakose, Emil and Nelson, Cara},
title = {Oral GLP ‐ 1RA TERN ‐601 for Adults With Obesity/Overweight: Placebo‐Controlled, Multiple‐Ascending‐Dose, Phase 1 and 2 Studies},
journal = {Obesity},
year = {2026},
doi = {10.1002/oby.70271}
}
EUVIMED